Hexamethylene bisacetamide as a chemopreventive agent in hamster cheek pouch tumorigenesis

Hong, 1993, Recent advances in head and neck cancer—larynx preservation and cancer chemoprevention: the seventeenth annual Richard and Hinda Rosenthal foundation award lecture, Cancer Res, 53, 5113 Shklar, 1980, Retinoid inhibition of lingual carcinogenesis, Oral Surg Oral Med Oral Pathol, 49, 325, 10.1016/0030-4220(80)90142-5 Hong, 1986, 13-Cis-retinoic acid in the treatment of oral leukoplakia, N Engl J Med, 315, 1501, 10.1056/NEJM198612113152401 Stich, 1988, Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with β-carotene and with β-carotene plus vitamin A, Int J Cancer, 42, 195, 10.1002/ijc.2910420209 Schwartz, 1990, The effect of carotenoids on the antitumour immune response in vivo and in vitro with hamster and mouse immune effectors, Ann NY Acad Sci, 587, 92, 10.1111/j.1749-6632.1990.tb00137.x Lippman, 1992, Retinoid chemoprevention of upper aerodigestive tract carcinogenesis, 93 Benner, 1993, Regression of oral leukoplakia with alpha-tocopherol: a community clinical oncology program (CCOP) chemoprevention study, J Natl Cancer Inst, 85, 44, 10.1093/jnci/85.1.44 Hong, 1990, Prevention of secondary primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck, N Engl J Med, 323, 795, 10.1056/NEJM199009203231205 Reuben, 1976, A new group of potent inducers of differentiation in murine erythroleukemia cells, 73, 862 Rabson, 1977, Hexamethylene bisacetamide induces morphologic changes and increased synthesis of procollagen in cell line from glioblastoma multiforme, 74, 5060 Palfrey, 1977, Induction of differentiation in mouse neuroblastoma cells by hexamethylene bisacetamide, Biochem Biophys Res Commun, 76, 937, 10.1016/0006-291X(77)91592-3 Egorin, 1987, Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion, Cancer Res, 47, 617 Young, 1988, Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals, Cancer Res, 48, 7304 Conley, 1989, Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580), Cancer Res, 49, 3436 Chun, 1986, Hexamethylene bisacetamide: a polar-planar compound entering clinical trials as a differentiating agent, Cancer Treat Rep, 70, 991 Page, 1986, Bioavailability and oral toxicity studies with hexamethylene bisacetamide (HMBA: NSC-95580) in beagle dogs, 27, 274 Ward, 1991, A phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube, Cancer Res, 51, 1803 Yura, 1993, Effect of sialoadenectomy and epidermal growth factor administration on 9,10-dimethyl-1,2-benzanthracene-induced tumor formation in hamster cheek pouch, Oral Surg Oral Med Oral Pathol, 76, 723, 10.1016/0030-4220(93)90042-3 Harada, 1995, Effect of local administration of epidermal growth factor on 9,10-dimethyl-1,2-benzanthracene-induced tumour formation in hamster cheek pouch, Oral Oncol, Eur J Cancer, 31B, 27, 10.1016/0964-1955(94)00035-3 Kelley, 1985, Gas chromatographic determination of hexamethylene bisacetamide in plasma and urine, Anal Lett, 18, 1043, 10.1080/00032718508069099 Shklar, 1972, Experimental oral pathology in the Syrian hamster, Prog Exp Tumor Res, 16, 518, 10.1159/000393387 Tanaka, 1995, Chemoprevention of oral carcinogenesis, Oral Oncol, Eur J Cancer, 31B, 3, 10.1016/0964-1955(94)00026-Z Milo, 1985, Inhibition of carcinogen-induced cellular transformation of human fibroblasts by drugs that interact with the poly(ADP-ribose) polymerase system, FEBS Lett, 179, 332, 10.1016/0014-5793(85)80546-9 Tseng, 1987, Prevention of tumorigenesis of oncogene-transformed rat fibroblasts with DNA site inhibitors of poly (ADP ribose) polymerase, 84, 1107 Alderson, 1991, Poly(ADP-ribosylation) processing as a target for the anti-tumor effects of the cell differentiating agent, hexamethylenebisacetamide, and the N6-substituted adenosines, Anti-Cancer Drugs, 2, 543, 10.1097/00001813-199112000-00004 Nakayasu, 1988, Deletion of transfected oncogenes from NIH 3T3 transformants by inhibitors of poly (ADP-ribose) polymerase, 85, 9066 Shima, 1989, Loss of the MYC gene amplified in human HL-60 cells after treatment with inhibitors of poly(ADP-ribose)polymerase or with dimethyl sulfoxide, 86, 7442 Cohen, 1964, The response of hamster submaxillary glands to experimentally induced carcinoma in the cheek pouch, J Dent Res, 43, 461, 10.1177/00220345640430032401 Breitman, 1990, Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60, Cancer Res, 50, 6268